Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up.Journal of pharmaceutical policy and practice · 2025
   Article
2. Hypecotumines A-D, new isoquinoline alkaloids with potential PCSK9 inhibition activity from Hypecoum erectum L.Natural products and bioprospecting · 2024
   Article
3. Phenotyping of Korean patients with better-than-expected efficacy of moderate-intensity statins using tensor factorization.PloS one · 2018
   Article
4. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes.Endocrinology and metabolism (Seoul, Korea) · 2017
   Article
5. PCSK9 as a therapeutic target for cardiovascular disease.Experimental and therapeutic medicine · 2017
   Article
6. PCSK9 inhibitors in the prevention of cardiovascular disease.Journal of thrombosis and thrombolysis · 2016
   Review
7. Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes.Stem cells international · 2016
   Review
8. New drugs for treating dyslipidemia: beyond statins.Diabetes & metabolism journal · 2015
   Review
9. Pharmacological treatment and therapeutic perspectives of metabolic syndrome.Reviews in endocrine & metabolic disorders · 2014
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.